Research & Development

Within the microscopic theater of the human body, a relentless surveillance network operates with such precision that most pathogens are neutralized long before symptoms ever appear. At the heart of this defensive perimeter are dendritic cells, the primary "sentinels" that bridge the gap between

The precision required to dismantle a tumor without devastating the surrounding healthy tissue remains one of the most elusive targets in modern oncology. While the pharmaceutical industry has long sought to perfect antibody-drug conjugates (ADCs), the technical reality often falls short of the

Ivan Kairatov brings a wealth of expertise to the table as a seasoned biopharma strategist with a specialized focus on the intersection of metabolic research and regulatory innovation. With years of experience navigating the complex R&D pipelines of the world’s leading pharmaceutical firms, he has

The traditional landscape of oncological drug development is currently undergoing a massive transformation as Oregon Health & Science University launches an ambitious $9.2 million initiative to redefine the accuracy of preclinical testing. By establishing the Knight Cancer Precision Biofabrication

The traditional paradigm of managing localized prostate cancer has long forced men into a difficult compromise between the clinical necessity of eradicating a tumor and the deeply personal desire to maintain their physical autonomy and quality of life. For decades, the standard path involved either

Ivan Kairatov has spent decades at the intersection of biopharmaceutical innovation and clinical research, witnessing firsthand how the silos between medical disciplines are beginning to crumble. As an expert in research and development, Kairatov has focused his career on how systemic biological